Association of the V122I Hereditary Transthyretin Amyloidosis Genetic Variant With Heart Failure Among Individuals of African or Hispanic/Latino Ancestry.

Importance Hereditary transthyretin (TTR) amyloid cardiomyopathy (hATTR-CM) due to the TTR V122I variant is an autosomal-dominant disorder that causes heart failure in elderly individuals of African ancestry. The clinical associations of carrying the variant, its effect in other African ancestry populations including Hispanic/Latino individuals, and the rates of achieving a clinical diagnosis in carriers are unknown. Objective To assess the association between the TTR V122I variant and heart failure and identify rates of hATTR-CM diagnosis among carriers with heart failure. Design, Setting, and Participants Cross-sectional analysis of carriers and noncarriers of TTR V122I of African ancestry aged 50 years or older enrolled in the Penn Medicine Biobank between 2008 and 2017 using electronic health record data from 1996 to 2017. Case-control study in participants of African and Hispanic/Latino ancestry with and without heart failure in the Mount Sinai BioMe Biobank enrolled between 2007 and 2015 using electronic health record data from 2007 to 2018. Exposures TTR V122I carrier status. Main Outcomes and Measures The primary outcome was prevalent heart failure. The rate of diagnosis with hATTR-CM among TTR V122I carriers with heart failure was measured. Results The cross-sectional cohort included 3724 individuals of African ancestry with a median age of 64 years (interquartile range, 57-71); 1755 (47%) were male, 2896 (78%) had a diagnosis of hypertension, and 753 (20%) had a history of myocardial infarction or coronary revascularization. There were 116 TTR V122I carriers (3.1%); 1121 participants (30%) had heart failure. The case-control study consisted of 2307 individuals of African ancestry and 3663 Hispanic/Latino individuals; the median age was 73 years (interquartile range, 68-80), 2271 (38%) were male, 4709 (79%) had a diagnosis of hypertension, and 1008 (17%) had a history of myocardial infarction or coronary revascularization. There were 1376 cases of heart failure. TTR V122I was associated with higher rates of heart failure (cross-sectional cohort: n = 51/116 TTR V122I carriers [44%], n = 1070/3608 noncarriers [30%], adjusted odds ratio, 1.7 [95% CI, 1.2-2.4], P = .006; case-control study: n = 36/1376 heart failure cases [2.6%], n = 82/4594 controls [1.8%], adjusted odds ratio, 1.8 [95% CI, 1.2-2.7], P = .008). Ten of 92 TTR V122I carriers with heart failure (11%) were diagnosed as having hATTR-CM; the median time from onset of symptoms to clinical diagnosis was 3 years. Conclusions and Relevance Among individuals of African or Hispanic/Latino ancestry enrolled in 2 academic medical center-based biobanks, the TTR V122I genetic variant was significantly associated with heart failure.

[1]  Sanjiv J. Shah,et al.  Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy , 2018, The New England journal of medicine.

[2]  S. Solomon,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[3]  S. Solomon,et al.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[4]  Tanya M. Teslovich,et al.  Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease , 2017, The New England journal of medicine.

[5]  J. Buxbaum,et al.  Transthyretin V122I (pV142I)* cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans , 2017, Genetics in Medicine.

[6]  Marylyn D. Ritchie,et al.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.

[7]  Scott M. Williams,et al.  The prevalence and distribution of the amyloidogenic transthyretin (TTR) V122I allele in Africa , 2016, Molecular genetics & genomic medicine.

[8]  Sanjiv J. Shah,et al.  Genotype and Phenotype of Transthyretin Cardiac Amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey). , 2016, Journal of the American College of Cardiology.

[9]  A. Hagège,et al.  Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. , 2016, European heart journal.

[10]  Kathleen F. Kerr,et al.  Genetic Diversity and Association Studies in US Hispanic/Latino Populations: Applications in the Hispanic Community Health Study/Study of Latinos. , 2016, American journal of human genetics.

[11]  J. Buxbaum,et al.  Prevalence of the amyloidogenic transthyretin (TTR) V122I allele in 14 333 African–Americans , 2015, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[12]  David Reich,et al.  The Genetic Ancestry of African Americans, Latinos, and European Americans across the United States , 2015, American journal of human genetics.

[13]  Carson C Chow,et al.  Second-generation PLINK: rising to the challenge of larger and richer datasets , 2014, GigaScience.

[14]  E. Boerwinkle,et al.  The amyloidogenic V122I transthyretin variant in elderly black Americans. , 2015, The New England journal of medicine.

[15]  J. Aviña-Zubieta,et al.  Validity of Heart Failure Diagnoses in Administrative Databases: A Systematic Review and Meta-Analysis , 2014, PloS one.

[16]  J. Berk,et al.  Transthyretin (TTR) Cardiac Amyloidosis , 2012, Circulation.

[17]  J. Koziol,et al.  Relation of clinical, echocardiographic and electrocardiographic features of cardiac amyloidosis to the presence of the transthyretin V122I allele in older African-American men. , 2011, The American journal of cardiology.

[18]  Xiaofeng Zhu,et al.  Genetic Background of Patients from a University Medical Center in Manhattan: Implications for Personalized Medicine , 2011, PloS one.

[19]  F. Salvi,et al.  Transthyretin-related amyloidoses and the heart: a clinical overview , 2010, Nature Reviews Cardiology.

[20]  J. Koziol,et al.  Significance of the amyloidogenic transthyretin Val 122 Ile allele in African Americans in the Arteriosclerosis Risk in Communities (ARIC) and Cardiovascular Health (CHS) Studies. , 2010, American heart journal.

[21]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[22]  P. Lavori,et al.  Transthyretin V122I in African Americans with congestive heart failure. , 2006, Journal of the American College of Cardiology.

[23]  Douglas G Altman,et al.  Interaction revisited: the difference between two estimates , 2003, BMJ : British Medical Journal.

[24]  D G Altman,et al.  Statistics notes: Interaction 3: How to examine heterogeneity , 1996 .

[25]  J. Reveille,et al.  Frequency and genetic background of the position 122 (Val----Ile) variant transthyretin gene in the black population. , 1991, American journal of human genetics.

[26]  M. Pras,et al.  Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy. , 1989, The Journal of clinical investigation.

[27]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.